Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 96Pancreatic Neoplasms 85Carcinoma, Non-Small-Cell Lung 79Ovarian Neoplasms 52Fallopian Tube Neoplasms 48Triple Negative Breast Neoplasms 42Lung Neoplasms 32Neoplasm Metastasis 27Squamous Cell Carcinoma of Head and Neck 23Neoplasms 19Breast Neoplasms, Male 18Endometrial Neoplasms 17Uterine Cervical Neoplasms 16Stomach Neoplasms 16Melanoma 16Brenner Tumor 16Carcinoma, Ovarian Epithelial 15Esophageal Neoplasms 14Adenocarcinoma of Lung 13Inflammatory Breast Neoplasms 11Cholangiocarcinoma 10Adenocarcinoma, Bronchiolo-Alveolar 9Urinary Bladder Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 8Oropharyngeal Neoplasms 8Carcinoma, Transitional Cell 8Adenocarcinoma Of Esophagus 8Mouth Neoplasms 7Esophageal Squamous Cell Carcinoma 7Colorectal Neoplasms 7

Interventions

pegfilgrastim 30Filgrastim 29Cyclophosphamide 10pegylated granulocyte colony-stimulating factor 8Docetaxel 8Etoposide 7Cytarabine 7Ciprofloxacin 6Cefepime 6Vancomycin 5Leucovorin 5Fluorouracil 5eflapegrastim 4Granulocyte Colony-Stimulating Factor 4Doxorubicin 4Peripheral Blood Stem Cell Transplantation 3Mitoxantrone 3Methotrexate 3Levofloxacin 3Irinotecan 3Idarubicin 3Daunorubicin 3Cyclosporine 3Caspofungin 3Carboplatin 3Amikacin 3trifluridine tipiracil drug combination 2plerixafor 2liposomal amphotericin B 2Vincristine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neutropenia × Taxes × Clear all
NCT00352300 2014-12-31

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

GOG Foundation

Phase 1 Completed
43 enrolled
Gynecologic

Communicable Diseases, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡